SAINT LAURENT, Quebec, April 30, 2014 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a Canadian drug delivery company focusing on oral drug delivery, today announced financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). In addition to advisory services and technological expertise, the funding provided by NRC-IRAP will support further development of a product for the treatment of central nervous system (CNS) diseases and disorders. The product will be based upon IntelGenx’ proprietary, oral thin film, VersaFilm™, technology.
Help employers find you! Check out all the jobs and post your resume.